Lantheus Holdings Inc (NASDAQ:LNTH) insider Cesare Orlandi sold 4,057 shares of Lantheus stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $18.06, for a total value of $73,269.42. Following the sale, the insider now owns 73,689 shares in the company, valued at $1,330,823.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Cesare Orlandi also recently made the following trade(s):
- On Thursday, January 31st, Cesare Orlandi sold 3,060 shares of Lantheus stock. The shares were sold at an average price of $16.56, for a total value of $50,673.60.
- On Friday, November 30th, Cesare Orlandi sold 7,055 shares of Lantheus stock. The shares were sold at an average price of $18.01, for a total value of $127,060.55.
NASDAQ LNTH opened at $17.47 on Monday. The company has a debt-to-equity ratio of 4.76, a quick ratio of 2.87 and a current ratio of 3.50. Lantheus Holdings Inc has a twelve month low of $12.59 and a twelve month high of $21.45. The company has a market cap of $671.98 million, a P/E ratio of 20.80, a PEG ratio of 3.53 and a beta of 1.47.
Several equities research analysts recently weighed in on the company. ValuEngine upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, December 1st. Zacks Investment Research lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Wednesday, February 6th. Finally, BidaskClub upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Friday, January 11th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $20.00.
WARNING: This story was published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://dakotafinancialnews.com/2019/02/11/lantheus-holdings-inc-lnth-insider-sells-73269-42-in-stock.html.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.